Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study

dc.authorid0000-0001-6384-2035
dc.authorid0000-0003-4222-3205
dc.authorid0000-0001-5038-6210
dc.authorid0000-0002-8356-3137
dc.authorid0000-0001-8434-6700
dc.authorid0000-0002-5094-219X
dc.authorid0000-0003-0190-8988
dc.contributor.authorWalli-Attaei, Marjan
dc.contributor.authorRosengren, Annika
dc.contributor.authorRangarajan, Sumathy
dc.contributor.authorBreet, Yolandi
dc.contributor.authorAbdul-Razak, Suraya
dc.contributor.authorAl Sharief, Wadeia
dc.contributor.authorAlhabib, Khalid F.
dc.date.accessioned2025-05-10T19:44:03Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground There is a paucity of data on the prevalence of risk factors and their associations with incident cardiovascular disease in women compared with men, especially from low-income and middle-income countries. Methods In the Prospective Urban Rural Epidemiological (PURE) study, we enrolled participants from the general population from 21 high-income, middle-income, and low-income countries and followed them up for approximately 10 years. We recorded information on participants' metabolic, behavioural, and psychosocial risk factors. For this analysis, we included participants aged 35-70 years at baseline without a history of cardiovascular disease, with at least one follow-up visit. The primary outcome was a composite of major cardiovascular events (cardiovascular disease deaths, myocardial infarction, stroke, and heart failure). We report the prevalence of each risk factor in women and men, their hazard ratios (HRs), and population-attributable fractions (PAFs) associated with major cardiovascular disease. The PURE study is registered with ClinicalTrials.gov, NCT03225586. Findings In this analysis, we included 155 724 participants enrolled and followed-up between Jan 5, 2005, and Sept 13, 2021, (90 934 [58.4%] women and 64 790 [41.6%] men), with a median follow-up of 10.1 years (IQR 8.5-12.0). At study entry, the mean age of women was 49.8 years (SD 9.7) compared with 50.8 years (9.8) in men. As of data cutoff (Sept 13, 2021), 4280 major cardiovascular disease events had occurred in women (age-standardised incidence rate of 5.0 events [95% CI 4.9-5.2] per 1000 person-years) and 4911 in men (8.2 [8.0-8.4] per 1000 person-years). Compared with men, women presented with a more favourable cardiovascular risk profile, especially at younger ages. The HRs for metabolic risk factors were similar in women and men, except for non-HDL cholesterol, for which high non-HDL cholesterol was associated with an HR for major cardiovascular disease of 1.11 (95% CI 1.01-1.21) in women and 1.28 (1.19-1.39) in men, with a consistent pattern for higher risk among men than among women with other lipid markers. Symptoms of depression had a HR of 1.09 (0.98-1.21) in women and 1.42 (1.25-1.60) in men. By contrast, consumption of a diet with a PURE score of 4 or lower (score ranges from 0 to 8), was more strongly associated with major cardiovascular disease in women (1.17 [1.08-1.26]) than in men (1.07 [0.99-1.15]). The total PAFs associated with behavioural and psychosocial risk factors were greater in men (15.7%) than in women (8.4%) predominantly due to the larger contribution of smoking to PAFs in men (ie, 1.3% [95% CI 0.5-2.1] in women vs 107% [8.8-12.6] in men). Interpretation Lipid markers and depression are more strongly associated with the risk of cardiovascular disease in men than in women, whereas diet is more strongly associated with the risk of cardiovascular disease in women than in men. The similar associations of other risk factors with cardiovascular disease in women and men emphasise the importance of a similar strategy for the prevention of cardiovascular disease in men and women. Copyright (C) 2022 Elsevier Ltd. All rights reserved.
dc.description.sponsorshipPopulation Health Research Institute; Hamilton Health Sciences Research Institute; Canadian Institutes of Health Research (Strategy for Patient-Oriented Research via the Ontario SPOR Support Unit); Heart and Stroke Foundation (ON, Canada); Ontario Ministry of Health and LongTerm Care; AstraZeneca (Canada); SanofiAventis (France); SanofiAventis (Canada); Boehringer Ingelheim (Germany); Boehringer Ingelheim (Canada); Servier; GlaxoSmithKline; Novartis; King Pharma; Fundacion ECLA (Estudios Clinicos Latino America); Independent University; Mitra and Associates; Hospital Alemao Oswaldo Cruz, Sao Paulo; Dairy Farmers of Canada; National Dairy Council (US); Public Health Agency of Canada; Champlain Cardiovascular Disease Prevention Network; Universidad de La Frontera [EXD05-0003]; National Center for Cardiovascular Diseases; ThinkTank Research Center for Health Development; Colciencias [6566-04-18062, 6517-777-58228]; Indian Council of Medical Research; Ministry of Science, Technology and Innovation of Malaysia [100-IRDC/BIOTEK 16/6/21 [13/2007], 07-05-IFN-BPH 010]; Ministry of Higher Education of Malaysia [600-RMI/LRGS/5/3 [2/2011]]; Universiti Teknologi MARA; Biostatistics & Data Repository Sector; National Institute of Health, Setia Alam; National Registration Department (JPN), Universiti Kebangsaan Malaysia [UKM-Hejim-Komuniti-15-2010]; United Nations Relief and Works Agency for Palestine Refugees in the Near East; International Development Research Centre, Canada; Philippine Council for Health Research and Development; Polish Ministry of Science and Higher Education, Wroclaw Medical University [290/W-PURE/2008/0]; Saudi Heart Association; Dr Mohammad Alfagih Hospital; Deanship of Scientific Research at King Saud University [RG -1436-013]; Saleh Hamza Serafi Chair for Research of Coronary Heart Disease, Umm AlQura University; North-West University; Netherlands Programme for Alternative Development; National Research Foundation; Medical Research Council of South Africa; South Africa Sugar Association; Faculty of Community and Health Sciences; Swedish state under the Agreement concerning research and education of doctors; Swedish Heart and Lung Foundation; Swedish Research Council [2018-02527]; Swedish Council for Health, Working Life and Welfare; King Gustaf V:s and Queen Victoria Freemason's Foundation; AFA Insurance; Metabolic Syndrome Society; AstraZeneca; Sanofi Aventis; Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences; Dubai Health Authority
dc.description.sponsorshipThe PURE study is funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute, the Canadian Institutes of Health Research (including through the Strategy for Patient-Oriented Research via the Ontario SPOR Support Unit), the Heart and Stroke Foundation (ON, Canada), and the Ontario Ministry of Health and LongTerm Care. The study was also funded by unrestricted grants from the following pharmaceutical companies: AstraZeneca (Canada), SanofiAventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma. And the study was also funded by several national and local organisations in participating countries as follows: Argentina: Fundacion ECLA (Estudios Clinicos Latino America); Bangladesh: Independent University and Mitra and Associates; Brazil: Hospital Alemao Oswaldo Cruz, Sao Paulo; Canada: an unrestricted grant from Dairy Farmers of Canada and the National Dairy Council (US), Public Health Agency of Canada, and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de La Frontera (EXD05-0003); China: National Center for Cardiovascular Diseases and ThinkTank Research Center for Health Development; Colombia: Colciencias (grant 6566-04-18062 and grant 6517-777-58228); India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia (grant number: 100-IRDC/BIOTEK 16/6/21 [13/2007], and 07-05-IFN-BPH 010), Ministry of Higher Education of Malaysia (grant number: 600-RMI/LRGS/5/3 [2/2011]), Universiti Teknologi MARA, Biostatistics & Data Repository Sector, National Institute of Health, Setia Alam, and National Registration Department (JPN), Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010); the Middle East: the United Nations Relief and Works Agency for Palestine Refugees in the Near East and International Development Research Centre, Canada; The Philippines: Philippine Council for Health Research and Development; Poland: Polish Ministry of Science and Higher Education (grant number: 290/W-PURE/2008/0), Wroclaw Medical University; Saudi Arabia: Saudi Heart Association, Dr Mohammad Alfagih Hospital, The Deanship of Scientific Research at King Saud University (research group number: RG -1436-013), Saleh Hamza Serafi Chair for Research of Coronary Heart Disease, Umm AlQura University; South Africa: The North-West University, and Netherlands Programme for Alternative Development, National Research Foundation, Medical Research Council of South Africa, The South Africa Sugar Association, Faculty of Community and Health Sciences; Sweden: grants from the Swedish state under the Agreement concerning research and education of doctors, the Swedish Heart and Lung Foundation, the Swedish Research Council (2018-02527), the Swedish Council for Health, Working Life and Welfare, King Gustaf V:s and Queen Victoria Freemason's Foundation, and AFA Insurance; Turkiye: Metabolic Syndrome Society, AstraZeneca, Sanofi Aventis; United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences and Dubai Health Authority, Dubai. Further details on the funding and participating countries and institutions, and on collaborating staff, are shown in the appendix (pp 3-8).
dc.identifier.doi10.1016/S0140-6736(22)01441-6
dc.identifier.endpage821
dc.identifier.issn0140-6736
dc.identifier.issn1474-547X
dc.identifier.issue10355
dc.identifier.pmid36088949
dc.identifier.scopus2-s2.0-85137286917
dc.identifier.scopusqualityQ1
dc.identifier.startpage811
dc.identifier.urihttps://doi.org/10.1016/S0140-6736(22)01441-6
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10795
dc.identifier.volume400
dc.identifier.wosWOS:000877580600020
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofLancet
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectCoronary-Heart-Disease
dc.subjectSmoking
dc.subjectMetaanalysis
dc.subjectMortality
dc.subjectSex
dc.titleMetabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study
dc.typeArticle

Dosyalar